The abstract is read at the publisher; the summary is JClub's.
Downstream purification of next-generation biotherapeutics requires modality-specific separation strategies, because their structural and physicochemical differences create distinct manufacturing challenges beyond mAb expertise.
- Why it matters: The field is shifting toward complex modalities with advantages over traditional drugs, but their unique properties make standard purification approaches insufficient for scalable, cost-effective production.
- What they did: This review summarizes major downstream processing developments from the last 5 years, covering chromatographic and nonchromatographic separations, process intensification, and automation and process control across multiple modalities.
- The result: The collected advances suggest purification processes must be tailored to each modality’s physicochemical characteristics, implying mAb manufacturing know-how alone cannot be directly transferred for these products.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.